VIA EMAIL ONLY January 26, 2018 Kerry Propper Chief Executive Officer Chardan Capital Markets, LLCMutual Termination Agreement • February 22nd, 2018 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products
February 22, 2018 PharmaCyte Biotech, Inc. 23046 Avenida de la Carlota Suite 600 Laguna Hills, CA 92653 Attention: Kenneth L. Waggoner Re: Financial Advisory, Offering and At the Market Offering (“ATM”)Financial Advisory Agreement • February 22nd, 2018 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products • New York
This letter agreement (“Agreement”) will confirm the basis upon which PharmaCyte Biotech, Inc. (“Company”) has engaged Aeon Capital, Inc. (“Aeon”) to act as the Company’s sole financial advisor and exclusive placement agent in connection with a planned offering of the Company’s shares of common stock (“Common Stock”), par value $0.0001 per share (“Transaction”).
